{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Borderline+Resectable+Pancreatic+Carcinoma&page=4",
    "query": {
      "condition": "Borderline Resectable Pancreatic Carcinoma",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 75,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Borderline+Resectable+Pancreatic+Carcinoma&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Borderline+Resectable+Pancreatic+Carcinoma&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T13:10:11.621Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03970252",
      "title": "Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Borderline Resectable Pancreatic Adenocarcinoma",
        "Resectable Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2019-07-24",
      "completion_date": "2024-05-25",
      "has_results": false,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-10-10T13:10:11.621Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03970252"
    },
    {
      "nct_id": "NCT03703063",
      "title": "Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "nab paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Onivyde",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "5-fu",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Benaroya Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2018-09-17",
      "completion_date": "2022-09-17",
      "has_results": false,
      "last_update_posted_date": "2021-01-27",
      "last_synced_at": "2026-10-10T13:10:11.621Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03703063"
    },
    {
      "nct_id": "NCT02843945",
      "title": "Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Directional Brachytherapy Source Implant",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "CivaTech Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2017-05-31",
      "completion_date": "2028-10-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-17",
      "last_synced_at": "2026-10-10T13:10:11.621Z",
      "location_count": 6,
      "location_summary": "Tampa, Florida • Chicago, Illinois • Oak Lawn, Illinois + 3 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02843945"
    },
    {
      "nct_id": "NCT05764720",
      "title": "Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Daily Adaptive External Beam Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Varian, a Siemens Healthineers Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2023-05-14",
      "completion_date": "2030-03-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-10T13:10:11.621Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Duarte, California • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05764720"
    },
    {
      "nct_id": "NCT02241551",
      "title": "Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Borderline Resectable Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine/nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "mFOLFIRINOX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nathan Bahary, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2014-12",
      "completion_date": "2017-03-03",
      "has_results": true,
      "last_update_posted_date": "2018-07-26",
      "last_synced_at": "2026-10-10T13:10:11.621Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02241551"
    },
    {
      "nct_id": "NCT01413022",
      "title": "FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "PF-04136309",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2012-04",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2016-09-19",
      "last_synced_at": "2026-10-10T13:10:11.621Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01413022"
    },
    {
      "nct_id": "NCT01836432",
      "title": "Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Pancreatic Carcinoma Non-resectable",
        "Locally Advanced Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "FOLFIRINOX",
          "type": "DRUG"
        },
        {
          "name": "Algenpantucel-L Immunotherapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "5-FU Chemoradiation",
          "type": "RADIATION"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "NewLink Genetics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 302,
      "start_date": "2013-05",
      "completion_date": "2017-03-24",
      "has_results": false,
      "last_update_posted_date": "2020-05-28",
      "last_synced_at": "2026-10-10T13:10:11.621Z",
      "location_count": 32,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 28 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01836432"
    },
    {
      "nct_id": "NCT07705919",
      "title": "DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Borderline Resectable Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Gadolinium-Chelate",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Point-of-care portable perfusion phantom (P4)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-10-01",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-10T13:10:11.621Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07705919"
    },
    {
      "nct_id": "NCT04005690",
      "title": "Targeted Pathway Inhibition in Patients With Pancreatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Locally Advanced Pancreatic Ductal Adenocarcinoma",
        "Metastatic Pancreatic Ductal Adenocarcinoma",
        "Stage II Pancreatic Cancer AJCC v8",
        "Stage III Pancreatic Cancer AJCC v8",
        "Stage IV Pancreatic Cancer AJCC v8",
        "Unresectable Pancreatic Ductal Adenocarcinoma",
        "Borderline Resectable Pancreatic Ductal Adenocarcinoma",
        "Resectable Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Onvansertib",
          "type": "DRUG"
        },
        {
          "name": "Azenosertib",
          "type": "DRUG"
        },
        {
          "name": "Saruparib",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2019-08-01",
      "completion_date": "2028-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-10-10T13:10:11.621Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04005690"
    },
    {
      "nct_id": "NCT02598349",
      "title": "Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Proton Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Surgical resection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Proton Collaborative Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2016-04",
      "completion_date": "2040-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-10T13:10:11.621Z",
      "location_count": 4,
      "location_summary": "Little Rock, Arkansas • Jacksonville, Florida • Warrenville, Illinois + 1 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Warrenville",
          "state": "Illinois"
        },
        {
          "city": "Flint",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02598349"
    }
  ]
}